Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib

The incidence of greater than or equal to grade 3 AEs, SAEs, AEs resulting in dose reduction/interruption/discontinuation, AESIs, and AEs resulting in death in the overall population

Time frame: At enrollment and every 3 months thereafter (up to 3 years)

Real-world progression-free survival (rwPFS) for 1L treatment with Iruplinalkib

Time frame: From the first administration of Iruplinalkib to the date of first documentation of disease progression, or death due to any cause, whichever occurs first (up to 3 years).

Time to treatment failure (TTF) for 1L treatment with Iruplinalkib

Time frame: From the first administration of Iruplinalkib to the date of first documentation of discontinuation of Iruplinalkib due to any cause (up to 3 years).

Event to first follow-up treatment or death (TFST) for 1L treatment with Iruplinalkib

Time frame: From the first administration of Iruplinalkib to the date of first documentation of initiation of next line of treatment, or death due to any cause, whichever occurs first (up to 3 years).